NPI: 1497828321 · NASHVILLE, TN 37203 · 207W00000X
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 23,000 | $565K |
| 2019 | 24,206 | $592K |
| 2020 | 22,224 | $580K |
| 2021 | 27,591 | $773K |
| 2022 | 25,829 | $705K |
| 2023 | 24,704 | $1.46M |
| 2024 | 18,359 | $1.29M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 67028 | 39,405 | 28,482 | $2.39M | |
| J0178 | Aflibercept injection | 2,488 | 1,477 | $1.22M |
| 92014 | 32,561 | 24,928 | $721K | |
| J9035 | Bevacizumab injection | 29,522 | 16,934 | $608K |
| 92134 | 49,209 | 36,600 | $493K | |
| Q5128 | Inj, cimerli, 0.1 mg | 1,290 | 720 | $221K |
| 92250 | 8,784 | 7,186 | $188K | |
| 99204 | 2,062 | 1,694 | $109K | |
| Q5124 | Inj. byooviz, 0.1 mg | 43 | 13 | $6K |
| 99223 | Prolong inpt eval add15 m | 43 | 38 | $5K |
| 99233 | Prolong inpt eval add15 m | 38 | 26 | $3K |
| 92235 | 78 | 60 | $3K | |
| J3590 | Unclassified biologics | 365 | 190 | $2K |
| J7999 | Compounded drug, noc | 25 | 12 | $87.83 |